A pH-Responsive Controlled Release Platform Based on Honeycomb MnO 2 /Carboxymethyl Chitosan/Oxidized Hyaluronic Acid for Multimodal Therapy of Breast Cancer
Molecular Pharmaceutics · 02.03.2026 · 23 (3) · 1942-1954
DOI: 10.1021/acs.molpharmaceut.5c01660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 29.01.2026. Verfasst von Hongyu Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Advanced Materials and Technology, School of Petrochemical Engineering, Changzhou University, Changzhou 213164, China. Hauptthemen laut MEDLINE: Chitosan, Hyaluronic Acid, Manganese Compounds, Oxides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Changzhou Municipal Science and Technology Bureau, National Natural Science Foundation of China.
Abstract (Originalsprache)
To enhance the therapeutic efficacy of breast cancer, multimodal therapy with the aid of a pH-responsive controlled release platform is proposed in this work. Indocyanine green (ICG) is loaded in honeycomb MnO2 (hMnO2) synthesized by a template method, which is coencapsulated with 5-fluorouracil (5-FU) in the hydrogels cross-linked between carboxymethyl chitosan (CMCS) and oxidized hyaluronic acid (OHA). The imine linkage (-HC═N-) between CMCS and OHA is hydrolyzed under weakly acidic conditions, leading to the release of 5-FU for chemotherapy and ICG/hMnO2. The hMnO2 can convert the optical energy of near-infrared (NIR) light into heat for photothermal therapy (PTT). Additionally, the hMnO2 can be reduced to Mn2+ at low pH and high glutathione (GSH) level, and the produced Mn2+ can further react with H2O2 to generate hydroxyl radicals (·OH) through a Fenton-like reaction for chemodynamic therapy (CDT). ICG can be simultaneously released during the reduction of hMnO2, which can catalyze the conversion of oxygen to singlet oxygen (1O2) upon exposure to NIR light for photodynamic therapy (PDT). Due to the synergistic effects of chemotherapy, PTT, CDT, and PDT, the developed ICG/hMnO2/5-FU/CMCS/OHA hydrogels can significantly inhibit the growth of the 4T1 mouse breast cancer cell line.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Advanced Materials and Technology, School of Petrochemical Engineering, Changzhou University, Changzhou 213164, China.
- The Fifth Department of Orthopedics and Traumatology, Changzhou Municipal Hospital of Traditional Chinese Medicine, Changzhou 213003, China.
Förderung
- Natural Science Foundation of Jiangsu Province
- Changzhou Municipal Science and Technology Bureau
- National Natural Science Foundation of China
- Administration of Traditional Chinese Medicine of Jiangsu Province
Zitieren
APA
Lin, H., Bian, H., Li, J., Xu, L., Jiang, T., & Kong, Y. (2026). A pH-Responsive Controlled Release Platform Based on Honeycomb MnO 2 /Carboxymethyl Chitosan/Oxidized Hyaluronic Acid for Multimodal Therapy of Breast Cancer. Molecular Pharmaceutics, 23(3), 1942-1954. https://doi.org/10.1021/acs.molpharmaceut.5c01660
Vancouver
Lin H, Bian H, Li J, Xu L, Jiang T, Kong Y. A pH-Responsive Controlled Release Platform Based on Honeycomb MnO 2 /Carboxymethyl Chitosan/Oxidized Hyaluronic Acid for Multimodal Therapy of Breast Cancer. Molecular Pharmaceutics. 2026;23(3):1942-1954. doi:10.1021/acs.molpharmaceut.5c01660
BibTeX
@article{Lin2026,
author = {Lin, Hongyu and Bian, Huwei and Li, Junyao and Xu, Laidi and Jiang, Tao and Kong, Yong},
title = {A pH-Responsive Controlled Release Platform Based on Honeycomb MnO 2 /Carboxymethyl Chitosan/Oxidized Hyaluronic Acid for Multimodal Therapy of Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {3},
pages = {1942--1954},
doi = {10.1021/acs.molpharmaceut.5c01660}
}
EUVIMED